Type 1 diabetes is diagnosed through a combination of blood sugar tests and, critically, autoantibody blood tests that confirm the immune system is attacking the insulin-producing cells in the pancreas. A standard diabetes diagnosis requires a fasting blood glucose of 126 mg/dL or higher, an A1C of 6.5% or above, or a random blood glucose of 200 mg/dL or more. But those numbers alone only confirm diabetes. Distinguishing type 1 from type 2 requires additional testing, and getting that distinction right matters because the two conditions demand very different treatment.
Blood Sugar Tests That Confirm Diabetes
The first step is confirming that blood sugar levels are in the diabetic range. Doctors typically use one or more of these tests:
- Fasting plasma glucose: 126 mg/dL or higher after at least eight hours without food or drink.
- A1C (hemoglobin A1C): 6.5% or higher, reflecting average blood sugar over the previous two to three months.
- Random plasma glucose: 200 mg/dL or higher, taken at any time regardless of when you last ate, typically alongside classic symptoms like extreme thirst, frequent urination, or unexplained weight loss.
- Oral glucose tolerance test (OGTT): 200 mg/dL or higher two hours after drinking a 75-gram sugar solution.
For the OGTT, you eat and drink normally in the days beforehand, then fast for eight hours before the test. A blood sample is drawn before you drink the sugar solution, then again at one and two hours after. Most people find the sugary drink unpleasant but tolerable.
In type 1 diabetes, these numbers are often dramatically elevated at the time of diagnosis, especially in children and teens. Many people first learn something is wrong when blood sugar climbs to 300 or 400 mg/dL and symptoms become impossible to ignore.
Autoantibody Tests That Identify Type 1
This is the step that separates a type 1 diagnosis from type 2. In type 1 diabetes, the immune system produces antibodies that attack the insulin-producing beta cells of the pancreas. A simple blood draw can detect these antibodies, and finding one or more of them confirms the autoimmune nature of the disease.
Five autoantibodies are currently used in diagnostic panels:
- GAD antibodies (GADA): The most commonly tested and often the first to appear. These target an enzyme found in beta cells.
- Insulin autoantibodies (IAA): Antibodies against insulin itself, particularly useful in young children.
- IA-2 antibodies: Target a protein on the surface of beta cells.
- ZnT8 antibodies: Target a zinc transporter involved in insulin storage. This is the most recently identified of the five.
- Islet cell antibodies (ICA): A broader test that detects antibodies against multiple components of the islet cells.
Not every person with type 1 diabetes tests positive for all five. Most test positive for at least one or two. A doctor will often order a panel that checks for several at once. The presence of two or more autoantibodies is a strong indicator of type 1 diabetes and is also used to identify people at risk before symptoms ever develop.
C-Peptide: Measuring Insulin Production
C-peptide is a byproduct released in equal amounts whenever the pancreas makes insulin. Measuring it tells doctors how much insulin your body is still producing on its own. In type 1 diabetes, C-peptide levels are very low or undetectable because the immune system has destroyed most of the beta cells. A fasting or random C-peptide level at or below 0.20 nmol/L is indicative of type 1 diabetes.
This test is especially valuable when the diagnosis is unclear. Someone with type 2 diabetes typically has normal or even elevated C-peptide levels because their pancreas still produces insulin; the problem is that their body doesn’t respond to it efficiently. A low C-peptide combined with positive autoantibodies gives a clear picture of type 1.
The Three Stages of Type 1 Diabetes
Type 1 diabetes doesn’t appear overnight. The autoimmune process can begin months or years before symptoms show up. Researchers and clinicians now recognize three distinct stages, which is changing how the disease is detected and managed early.
In Stage 1, the immune attack has started. Two or more autoantibodies are present in the blood, but blood sugar levels are still normal and there are no symptoms. Most people at this stage have no idea anything is happening. Stage 1 is typically discovered through screening programs, particularly for children with a family history of type 1 diabetes.
In Stage 2, autoantibodies are still present, and blood sugar levels have become abnormal, though not yet high enough to cause noticeable symptoms. The beta cells are losing function, and progression to Stage 3 is likely.
Stage 3 is clinical type 1 diabetes. Blood sugar is high, symptoms are present, and the person needs insulin. This is the stage at which most people are diagnosed. The goal of screening programs is to catch the disease at Stage 1 or 2, which can delay progression and, importantly, reduce the risk of a dangerous first presentation.
When Type 1 Is First Caught in an Emergency
A significant number of type 1 diagnoses happen during a medical emergency called diabetic ketoacidosis, or DKA. This occurs when the body has so little insulin that it starts breaking down fat for energy at a dangerous rate, producing acids called ketones that make the blood too acidic. DKA is diagnosed when blood sugar exceeds 250 mg/dL, blood pH drops below 7.3, bicarbonate is below 18, and ketones are present in the blood.
Symptoms of DKA include nausea and vomiting, abdominal pain, fruity-smelling breath, rapid breathing, and confusion. It can progress to a life-threatening state quickly. In children especially, DKA is often the event that leads to the initial diabetes diagnosis because the warning signs of type 1 were missed or developed too fast for anyone to notice. Early screening and awareness of symptoms like increased thirst, frequent urination, bedwetting in previously dry children, and unexplained weight loss can help catch type 1 before it reaches this point.
Why Adults With Type 1 Are Often Misdiagnosed
About 40% of adults who develop type 1 diabetes are initially misdiagnosed with type 2. This happens because most people, including some doctors, associate type 1 with childhood. When a 35-year-old presents with high blood sugar, the default assumption is often type 2, and treatment begins with oral medications rather than insulin.
The misdiagnosis can persist for months or years until the oral medications stop working and the person’s blood sugar becomes dangerously uncontrolled. The key red flags that should prompt autoantibody and C-peptide testing in an adult include a normal or lean body weight, no signs of insulin resistance, rapid deterioration despite standard type 2 treatment, and a personal or family history of autoimmune conditions like thyroid disease or celiac disease.
LADA: Type 1 That Develops Slowly in Adults
A form of autoimmune diabetes called latent autoimmune diabetes in adults, or LADA, blurs the line between type 1 and type 2. People with LADA are typically diagnosed after age 30, have positive autoantibodies (most often GAD), and don’t need insulin right away. They can often manage blood sugar with oral medications for six months or longer before beta cell destruction progresses to the point that insulin becomes necessary.
LADA is most commonly misdiagnosed as type 2 diabetes. Doctors should consider LADA in anyone diagnosed with type 2 who is under 50, has a BMI of 27 or lower, or has a personal or family history of autoimmune disease. Autoantibody testing, particularly for GAD antibodies, is the most reliable way to identify LADA and ensure the right treatment plan is in place before beta cell function declines further.
What to Expect During the Diagnostic Process
If your doctor suspects type 1 diabetes, expect a combination of the tests described above, usually starting with basic blood sugar measurements and then moving to autoantibody testing and C-peptide. Most of these are standard blood draws that can be done in a single visit. The autoantibody panel may take several days to a week for results, depending on the lab.
For children being screened due to family history, the process is the same: a blood draw checking for autoantibodies. If two or more come back positive, the child is in Stage 1 and will be monitored with periodic blood sugar testing to track progression. The FDA has approved a treatment that can delay the onset of Stage 3 type 1 diabetes in people identified at Stage 2, making early screening more actionable than it has ever been.
If you or your child already has symptoms, diagnosis is usually fast. A random blood glucose over 200 mg/dL plus classic symptoms, confirmed with an autoantibody test, is often enough. The priority then shifts immediately to starting insulin and stabilizing blood sugar.